Trial Search Results

Human Salivary Gland Disposition of Alda-341 in Patients Undergoing Salivary Gland Surgery

The purpose of this study is determine salivary gland disposition of d-limonene, the primary component in citrus peel and a common dietary supplement.

Salivary gland tissue and saliva will be collected to determine concentration of d-limonene and its metabolites in these tissues.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):

Intervention(s):

  • Drug: Alda-341

Phase:

Early Phase 1

Eligibility


Inclusion Criteria:

   - Elected to undergo surgery for recent diagnosis of parotid or submandibular gland
   tumor

   - Ability to adhere to study visit schedule and other protocol requirements

   - Operable candidate base on the surgeon's note

   - Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

   - Nursing or pregnant

   - Diagnosis of kidney disease, history of renal disease with creatinine > 1.5 mg/dL, or
   currently on dialysis

   - Diagnosis of end stage liver disease

   - Any unstable medical condition

   - Use of chemotherapy or radiotherapy within 4 weeks before first dose of study dietary
   supplement

   - Unwilling to stop dietary supplements 3 weeks before first dose of study dietary
   supplement

Ages Eligible for Study

18 Years - 85 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305